Karen Merritt: Hoping for labelling updates to recommend pre-treatment DPD deficiency testing
Karen Merritt, Patient Advocate-Advocates for Universal DPD, shared a post on LinkedIn:
“After the FDA and American Association for Cancer Research workshop discussing DPD deficiency testing, the FDA made a Safety Announcement to, again, raise the awareness of the labelling changes as well as the risks to patients from 5FU and capecitabine chemo if a patient is deficient of the DPD enzyme.
Testing is the ONLY way to determine if one is DPD deficient. We are still hoping for labelling updates to recommend pre-treatment DPD deficiency testing- this would be a further step towards better patient safety with this cornerstone chemotherapy.
Excerpt from safety announcement: “The FDA will continue to monitor this safety issue and evaluate the evolving landscape and impact of DPD deficiency on the safety of capecitabine and fluorouracil; additional regulatory actions will be considered.
The FDA urges patients and healthcare providers to report side effects involving capecitabine or 5-FU products to the FDA MedWatch” National Comprehensive Cancer Network (NCCN) still fails to update the guidelines to recommend pre-treatment DPD deficiency testing, yet many NCCN-member institutions have implemented universal testing such as Dana Farber Cancer Institute, Mass General and Duke Cancer Institute.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023